Titre:
  • PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Auteur:Loibl, Sibylle; Majewski, Ian IJ; Guarneri, V; Nekljudova, Valentina; Holmes, E; Bria, E; Denkert, Carsten; Schem, Christian; Sotiriou, Christos; Loi, S; Untch, M; Conte, Pier Franco; Bernards, René; Piccart-Gebhart, Martine; von Minckwitz, G; Baselga, J
Informations sur la publication:Annals of oncology
Statut de publication:Publié, 2019-01
Sujet CREF:Cancérologie
Sciences bio-médicales et agricoles
Médecine pathologie humaine
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdy536
info:pii/5281259
info:pmid/30624609